The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Dr. Singh proposes upskilling medicos with AI, Quantum and other newer technologies to meet the changing requirements of patient care
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
India has the highest prevalence of diabetes globally, with an estimated 77 million people living with the condition and an expected 134 million cases by 2045
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Subscribe To Our Newsletter & Stay Updated
